Taysha Gene Therapies, Inc. TSHA
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -25.64%
- 1 year
- -8.30%
- Market cap
- 1.33B
- Revenue (ttm)
- 5.49M
- EPS (ttm)
- -0.41
- Shares out
- 325.83M
- Forward P/E
- -8.84
- YTD return
- -25.64%
- 1-year return
- -8.30%
- Volume
- 1.72M
- Avg volume
- 3.54M
- Open
- 4.05
- Previous close
- 4.00
- Day's range
- 3.92 – 4.16
- 52-week range
- 3.46 – 7.30
- Beta
- 1.31
- Analysts
- Strong Buy
- Price target
- 13.00 (+217.8%)
- Earnings date
- Nov 3, 2026
2Y +2.75 (+205.22%)
Key statistics
- Enterprise value
- 904.64M
- PEG ratio
- 0.00
- Price / sales
- 242.96
- Price / book
- 3.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -80.97M
- Total cash
- 455.41M
- Total debt
- 56.71M
- Return on equity
- -47.05%
- Short % of float
- 15.98%
- 50-day average
- 4.78
- 200-day average
- 5.32
Analyst view
Consensus: strong buy
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.12857 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.11327 | -0.13 | -0.02 | -14.77% |
| May 6, 2026 | Mar 31, 2026 | -0.10 | -0.12 | -0.02 | -20.00% |
| Mar 19, 2026 | Dec 31, 2025 | -0.11 | -0.08 | +0.03 | +27.27% |
| Nov 4, 2025 | Sep 30, 2025 | -0.09 | -0.09 | 0.00 | 0.00% |
| Aug 12, 2025 | Jun 30, 2025 | -0.07 | -0.09 | -0.02 | -28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | init | — | Outperform |
| Jul 21, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 2, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Jun 30, 2026 | Needham | main | Buy | Buy |
| Jun 30, 2026 | Baird | main | Outperform | Outperform |
| Jun 23, 2026 | BMO Capital | main | Outperform | Outperform |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tayshagtx.com
News
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell? 
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis 
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting 
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting 
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating 
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval 
These 3 Risky Stocks Could Be Sitting on 100% Upside 
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Your note
Sign in to keep a note on TSHA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAM KAMRAN | Chief Financial Officer | Sale | Feb 3, 2026 | 1,442,130 |
| DONENBERG PHILLIP BRIAN | Director | Stock Award(Grant) | May 31, 2026 | 241,289 |
| LONG ALISON S | Director | Stock Award(Grant) | May 31, 2026 | 127,178 |
| MANNING PAUL B. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 29, 2025 | 0 |
| NAGENDRAN SUKUMAR | Officer and Director | Sale | Jul 9, 2026 | 936,410 |
| NOLAN SEAN PATRICK | Chief Executive Officer | Sale | Jan 25, 2026 | 4,443,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.33% | 23,888,888 | 97.71M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.23% | 23,555,648 | 96.34M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.97% | 22,713,118 | 92.90M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 20,691,927 | 84.63M | Jun 29, 2026 |
| Vestal Point Capital, LP | 5.96% | 19,415,000 | 79.41M | Jun 29, 2026 |
| Morgan Stanley | 5.06% | 16,487,479 | 67.43M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80% | 9,138,043 | 37.37M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.12% | 6,895,325 | 28.20M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58% | 5,138,803 | 21.02M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.28% | 4,170,948 | 17.06M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.93% | 3,044,554 | 12.45M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.81% | 2,626,937 | 10.74M | Aug 30, 2026 |